Study on the efficacy and mechanism of transcranial direct current stimulation (tDCS) combined with attention-biased training (ABT) in antipsychotic drug induced weight gain

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400081936

Enrollment

Unknown

Registered

2024-03-15

Start date

2024-03-15

Completion date

Unknown

Last updated

2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

True stimulus group :Transcranial direct current stimulation (tDCS) true stimulation combined with attentional bias training (ABT)

false stimulus group:Transcranial direct current stimulation (tDCS) false stimulation combined with attentional bias training (ABT)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: a. Meets the Diagnostic criteria for schizophrenia in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). b. Aged 18-65 years (when informed consent is obtained), with at least 6 years of schooling. c. Stable dose of olanzapine for at least 6 weeks prior to enrollment, no other antipsychotics combined, and clinically significant weight gain (=7%) after olanzapine treatment. d. Patients voluntarily participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: a. Mental disorders other than schizophrenia, such as affective disorders, anxiety spectrum disorders, etc.; Or comorbidities other mental disorders, such as mental retardation, substance dependence, personality disorders, etc. b. A history of seizures, stroke, or brain injury; Implant any metal device in the head; Frequent or severe headache or dizziness; Suffering from other serious or unstable physical diseases; A history of alcohol or drug abuse. c. Previous (within the last 6 months) or current electroconvulsive therapy. d. Participants in any other clinical trial within 30 days prior to enrollment; There are MRI contraindications, such as cochlear implants, cardiac pacemakers, metal dentures, etc. e. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale, VAS;The General-Food Craving Questionnaire-Trait, G-FCQ-T ;	—

Secondary

Measure	Time frame
Positive and Negative Syndrome Scale, PANSS;Hamilton Anxiety Scale, HAMA;Hamilton Depression Scale, HAMD;Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery, MCCB;Neuropeptide Y;Ghrelin;Leptin;	—

Countries

China

Contacts

Public ContactNa Hu

Beijing Huilongguan Hospital

foxlehu@163.com+86 135 2111 5481

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026